NCT00560794: Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
- State
- Completed
- Phase
- Phase 2
- People
- 21 taking part
- Started
- Jan 2008
- Primary completion
- Sep 2009
- Arms
- Blinatumomab
- Results
- Posted on the registry
- 20 Nov 2007: Trial registered
- 7 Jan 2015: Trial results posted